Clearside Biomedical Inc expected to post a loss of 10 cents a share - Earnings Preview

Clearside Biomedical,

08/08/2025 13:51

Clearside Biomedical Inc CLSD.OQ CLSD.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Alpharetta Georgia-based  company is expected to report a 88.9% increase in revenue to $170 thousand from $90 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Clearside Biomedical Inc is for a loss of 10 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Clearside Biomedical Inc is $5.00, about 92.3% above its last closing price of $0.38

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.11
-0.11
-0.11
Met
-1.3
Dec. 31 2025
-0.04
-0.10
-0.10
Met
-2.9
Sep. 30 2024
-0.12
-0.12
-0.10
Beat
19.5​
Jun. 30 2024
-0.13
-0.13
-0.10
Beat
25.9
​​Mar. 31 2024
-0.14
-0.14
-0.15
Missed
-9
Dec. 31 2023
-0.08
-0.09
-0.08
Beat
8.6​
Sep. 30 2023
-0.16
-0.15
-0.15
Met
3.2
Jun. 30 2023
-0.14
-0.14
-0.15
Missed
-5.9

This summary was machine generated August 8 at 12:51 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)